Chronic kidney disease

2023 - 1 - 10

Post cover
Image courtesy of "Business Wire"

WellSky® Partners With Panoramic Health to Deliver Superior ... (Business Wire)

WellSky capabilities strengthen the ability of Panoramic to provide holistic patient care and manage the complex needs of ESRD and CKD patients.

Panoramic Health is the nation’s leading integrated physician-led value-based kidney care organization, with more than 800 providers, supporting nephrologists who provide care across 19 states. and a leader in the innovation of kidney care, to provide higher quality and more cost effective care to patients living with chronic kidney disease (CKD) and end-stage renal disease (ESRD). In today’s value-based care environment, WellSky helps providers, payers, health systems, and community organizations scale processes, improve collaboration for growth, harness the power of data analytics, and achieve better outcomes by further connecting clinical and social care. These capabilities include proprietary quality analytics that identify post-acute providers best equipped to care for these high-risk patients and increase the number of patients discharged home that can be successfully supported by Panoramic Health’s multi-disciplinary care coordination teams. Our proven software, analytics, and services power better outcomes and lower costs for stakeholders across the health and community care continuum. Through its partnership with WellSky, Panoramic Health will gain access to a national connected network of acute and post-acute providers that use WellSky solutions for their transition of care workflows.

Post cover
Image courtesy of "Medical Xpress"

Group summarizes new guidelines for treating patients with diabetes ... (Medical Xpress)

The latest clinical practice guideline from the Kidney Disease: Improving Global Outcomes (KDIGO) organization offers advice for treating patients with ...

[DOI: 10.7326/M22-2904](https://dx.doi.org/10.7326/M22-2904) The KDIGO guideline update is based upon literature searches last conducted in December 2021, limiting the searches to randomized controlled trials only, and updated these searches in February 2022 at the time of the public review. A synopsis published in Annals of Internal Medicine focuses on the key recommendations pertinent to the following issues: comprehensive care, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and educational and integrated care approaches to management.

Post cover
Image courtesy of "2 Minute Medicine"

DART improves treatment decision-making for patients with chronic kidney disease (2 Minute Medicine)

Patients with chronic kidney disease (CKD) who used Decision-Aid for Renal Therapy (DART) demonstrated improved decision quality compared to those receiving care as usual. 2. Patients who used DART had increased knowledge regarding treatment options ...

As compared to the placebo group, patients in the DART group had knowledge improvement at three months (mean difference 9.0; 95% CI, 4.6 to 13.4), six months (mean difference, 9.4; 95% CI, 5.1 to 13.8), and 18 months (mean difference, 5.9; 95%CI, 1.4 to 10.3). Decisional conflict scores improved in the DART group at three- and six-month follow-up with mean differences of -7.9 (95% Confidence Interval [CI], -12.0 to -3.8) and -8.5 (95% CI, -13.0 to -3.9), respectively. [2 Minute Medicine, Inc](http://www.2minutemedicine.com). Inquire about licensing [here](http://www.2minutemedicine.com/license-content/). Preference for conservative management was increased from baseline (11.5%) in the DART group to 16.9% at three months and 19.9% at six months. Decisional conflict scores were significantly improved for individuals in the DART group at both three and six-month follow-ups. Improvements were also seen in the DART group across various subscales of the decisional conflict scale. Fewer individuals were “unsure” about treatment preferences over time in the DART group as compared to the control group. A total of 363 participants were randomized (180 to control and 183 to DART) and baseline characteristics between the two groups were balanced. In-Depth [randomized controlled trial]: This multicenter, randomized control trial compared the effectiveness of DART to standard educational materials for improving decisional quality in CKD patients. Patient knowledge was improved for both control and DART groups and these improvements persisted at 6 and 18-month follow-ups. The present study evaluated decision-making in patients with CKD with and without the DART tool.

Explore the last week